CD59: a promising target for tumor immunotherapy.

Zhang, Ronghua; Liu, Qiaofei; Liao, Quan; Zhao, Yupei

Zhang, Ronghua; Liu, Qiaofei; Liao, Quan; Zhao, Yupei.

Afiliação

Zhang R; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, PR China.
Liu Q; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, PR China.
Liao Q; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, PR China.
Zhao Y; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, PR China.

Future Oncol ; 14(8): 781-791, 2018 Apr.

Article em En | MEDLINE | ID: mdl-29521526

Assuntos

Antígenos CD59/genética; Imunoterapia; Neoplasias/tratamento farmacológico; Antígenos CD59/antagonistas & inibidores; Antígenos CD59/imunologia; Humanos; Neoplasias/imunologia; Microambiente Tumoral/genética; Microambiente Tumoral/imunologia

Palavras-chave

CD59; complement; immunotherapy; microenvironment; tumor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos CD59 / Imunoterapia / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google